Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_4
1
25%
Ph early_phase_1
2
50%

Phase Distribution

2

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
2(66.7%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Other(1)

Detailed Status

Completed2
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (66.7%)
Phase 41 (33.3%)

Trials by Status

unknown125%
recruiting125%
completed250%

Recent Activity

1 active trials
Showing 4 of 4
completed

NUCALA® Special Drug Use Investigation (EGPA, Long-term)

NCT03557060
recruitingphase_4

Complete Remission After Treatment With Biologics for Nasal Polyps

NCT07268313
completedearly_phase_1

Mepolizumab for the Treatment of Chronic Spontaneous Urticaria

NCT03494881
unknownearly_phase_1

Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers

NCT05353179

Clinical Trials (4)

Showing 4 of 4 trials
NCT03557060

NUCALA® Special Drug Use Investigation (EGPA, Long-term)

Completed
NCT07268313Phase 4

Complete Remission After Treatment With Biologics for Nasal Polyps

Recruiting
NCT03494881Early Phase 1

Mepolizumab for the Treatment of Chronic Spontaneous Urticaria

Completed
NCT05353179Early Phase 1

Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4